Symbiotec Pharmalab stands out as the preferred long-term pick, backed by SBI Securities’ ‘Subscribe’ rating and Master Capital’s positive view on its specialised business.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.